InvestorStream presents insights across the small cap space, from company interviews to analyst insights, while profiling some of the sector’s sharpest minds.
Joined June 2017
- Tweets 12,910
- Following 1,529
- Followers 2,116
- Likes 22,641
4,095 Photos and videos
Q: W/ mineralisation observed from 84m to 256m downhole & remaining open at depth, & w/ drilling to continue, what key milestones investors should watch for as @SHMining $SUH looks to convert growing geological footprint into additional JORC resources? youtu.be/_APzzBM-3gc
26
Q: Assay results are expected w/in next 4-6 weeks. Beyond grades themselves, what geological indicators will you be looking for to determine whether drilling is vectoring toward a higher-grade core within Llahuin #porphyry system? youtu.be/_APzzBM-3gc @SHMining $SUH #Copper
29
From Investor Stream desk:
📢 @LodestarASX $LSR maiden drilling at Three Saints confirms #IOCG system w/ Cu-Au-Co-Mo mineralisation from ~196m to EOH
⚡ System >1.6km & open in all directions; multiple mineralising events identified. Magnetic reprocessing underway to target core
66
Q: W/ mineralisation observed from 84m to 256m downhole & remaining open at depth, & w/ drilling to continue, what key milestones investors should watch for as @SHMining $SUH looks to convert growing geological footprint into additional JORC resources? youtu.be/_APzzBM-3gc
27
Q: Assay results are expected w/in next 4-6 weeks. Beyond grades themselves, what geological indicators will you be looking for to determine whether drilling is vectoring toward a higher-grade core within Llahuin #porphyry system? youtu.be/_APzzBM-3gc @SHMining $SUH #Copper
30
TRP-8802 validated the opportunity in treatment-resistant #IBS. The next question is whether $ENP ’s proprietary IV-infused #psilocin therapy can unlock even greater consistency, control and scalability. Dr Erin Mauney explains. youtu.be/KAnfXq8mdmE #biotech @Entropy_Neuro
34
TRP-8802 helped validate #IBS indication & gut-brain mechanism. we asked Dr Erin Mauney how $ENP ’s proprietary IV-infused #psilocin therapy, TRP-8803, could build on these findings and potentially deliver an even more consistent treatment experience. youtu.be/KAnfXq8mdmE
41
As #psychedelic therapies continue to evolve, understanding how & why they work is becoming just as important as clinical outcomes. Dr Erin Mauney explains what latest #IBS data reveals about gut-brain axis & future treatment opportunities. youtu.be/KAnfXq8mdmE $ENP
24
One of the most important findings from $ENP’s Phase 2a #IBS study wasn't just the response rate. It was the evidence supporting a potential underlying mechanism of action through the gut-brain axis. youtu.be/KAnfXq8mdmE #biotech @Entropy_Neuro
19
Q: Could the key to treating #IBS lie beyond the gut itself? Dr Erin Mauney discusses how the study's mechanistic findings are helping researchers better understand the role of the gut-brain axis in IBS. youtu.be/KAnfXq8mdmE $ENP #biotech @Entropy_Neuro
22
The Phase 2a #IBS study delivered more than strong efficacy data. Researchers also observed a link between symptom improvement & changes in key psychological measures, providing further support for the gut-brain axis hypothesis. youtu.be/KAnfXq8mdmE $ENP @Entropy_Neuro
22
Following the presentation of $ENP's Phase 2a #IBS results, Principal Investigator Dr Erin Mauney discusses clinical outcomes, gut-brain connection & why study's findings could represent important step forward in treatment-resistant #IBS. youtu.be/KAnfXq8mdmE @Entropy_Neuro
25
Q:What happens when therapy delivers meaningful improvements in patients who've failed multiple treatment options? Dr Erin Mauney breaks down clinical insights behind $ENP's TRP-8802 IBS data & what it could mean for millions living w/ #IBS. youtu.be/KAnfXq8mdmE @Entropy_Neuro
27
$ENP Phase 2a IBS study showed 75% response rate in treatment-resistant patients, one of strongest efficacy signals in indication. We spoke w/ Principal Investigator Dr Erin Mauney on what’s driving results & significance for #IBS treatment youtu.be/KAnfXq8mdmE @Entropy_Neuro
21
TRP-8802 validated the opportunity in treatment-resistant #IBS. The next question is whether $ENP ’s proprietary IV-infused #psilocin therapy can unlock even greater consistency, control and scalability. Dr Erin Mauney explains. youtu.be/KAnfXq8mdmE #biotech @Entropy_Neuro
23
TRP-8802 helped validate #IBS indication & gut-brain mechanism. we asked Dr Erin Mauney how $ENP ’s proprietary IV-infused #psilocin therapy, TRP-8803, could build on these findings and potentially deliver an even more consistent treatment experience. youtu.be/KAnfXq8mdmE
34
As #psychedelic therapies continue to evolve, understanding how & why they work is becoming just as important as clinical outcomes. Dr Erin Mauney explains what latest #IBS data reveals about gut-brain axis & future treatment opportunities. youtu.be/KAnfXq8mdmE $ENP
17
One of the most important findings from $ENP’s Phase 2a #IBS study wasn't just the response rate. It was the evidence supporting a potential underlying mechanism of action through the gut-brain axis. youtu.be/KAnfXq8mdmE #biotech @Entropy_Neuro
19